$SYRE
Spyre Therapeutics, Inc.

2017 Q4 Form 10-K Financial Statement

#000156459018005404 Filed on March 13, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2017 Q2
Revenue $1.483M $1.261M $1.479M
YoY Change 18.93% 9.75% 7.72%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.320M $3.020M $2.360M
YoY Change 13.17% 45.89% -3.67%
% of Gross Profit
Research & Development $5.790M $6.239M $5.835M
YoY Change 22.15% 15.75% 32.01%
% of Gross Profit
Depreciation & Amortization $70.00K $70.00K $60.00K
YoY Change 133.33% 75.0% 100.0%
% of Gross Profit
Operating Expenses $8.110M $6.239M $8.199M
YoY Change 19.44% -16.26% 19.38%
Operating Profit -$6.627M -$7.998M -$6.720M
YoY Change 19.56% 26.93% 22.29%
Interest Expense $150.0K $140.0K $100.0K
YoY Change 114.29% 100.0% 42.86%
% of Operating Profit
Other Income/Expense, Net -$10.00K $124.0K $88.00K
YoY Change 0.0% -1340.0% 35.38%
Pretax Income -$6.480M -$7.870M -$6.630M
YoY Change 18.25% 26.12% 22.1%
Income Tax
% Of Pretax Income
Net Earnings -$6.483M -$7.874M -$6.632M
YoY Change 18.24% 26.23% 22.14%
Net Earnings / Revenue -437.15% -624.43% -448.41%
Basic Earnings Per Share
Diluted Earnings Per Share -$390.6K -$479.6K -$469.9K
COMMON SHARES
Basic Shares Outstanding 16.45M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $50.30M $55.70M $63.40M
YoY Change -20.79% -18.09% -13.86%
Cash & Equivalents $12.82M $13.16M $26.93M
Short-Term Investments $37.50M $42.60M $36.50M
Other Short-Term Assets $1.600M $1.300M $1.600M
YoY Change -5.88% -38.1% -11.11%
Inventory
Prepaid Expenses
Receivables $3.100M $2.500M $1.200M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $55.00M $59.50M $66.20M
YoY Change -17.2% -17.02% -13.92%
LONG-TERM ASSETS
Property, Plant & Equipment $900.0K $800.0K $802.0K
YoY Change 50.25% 166.67% 112.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $100.0K $139.0K
YoY Change 400.0% 672.22%
Total Long-Term Assets $1.100M $1.000M $941.0K
YoY Change 72.14% 150.0% 138.23%
TOTAL ASSETS
Total Short-Term Assets $55.00M $59.50M $66.20M
Total Long-Term Assets $1.100M $1.000M $941.0K
Total Assets $56.10M $60.50M $67.14M
YoY Change -16.35% -16.09% -13.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $400.0K $600.0K $634.0K
YoY Change 138.1% 20.0% 82.18%
Accrued Expenses $5.200M $4.200M $3.700M
YoY Change 40.54% 35.48% 23.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.629M $4.900M $4.418M
YoY Change 41.97% 28.95% 29.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $111.0K $100.0K $122.0K
YoY Change -15.91%
Total Long-Term Liabilities $111.0K $100.0K $122.0K
YoY Change -15.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.629M $4.900M $4.418M
Total Long-Term Liabilities $111.0K $100.0K $122.0K
Total Liabilities $5.740M $5.000M $4.540M
YoY Change 40.1% 28.21% 33.53%
SHAREHOLDERS EQUITY
Retained Earnings -$58.16M
YoY Change 73.31%
Common Stock $2.000K $2.000K
YoY Change 100.0% 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.34M $55.50M $62.60M
YoY Change
Total Liabilities & Shareholders Equity $56.10M $60.50M $67.14M
YoY Change -16.35% -16.09% -13.14%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2017 Q2
OPERATING ACTIVITIES
Net Income -$6.483M -$7.874M -$6.632M
YoY Change 18.24% 26.23% 22.14%
Depreciation, Depletion And Amortization $70.00K $70.00K $60.00K
YoY Change 133.33% 75.0% 100.0%
Cash From Operating Activities -$5.880M -$7.370M -$5.940M
YoY Change 35.17% 25.55% 28.29%
INVESTING ACTIVITIES
Capital Expenditures -$190.0K -$110.0K -$50.00K
YoY Change 58.33% -44.44%
Acquisitions
YoY Change
Other Investing Activities $5.040M -$6.180M $4.570M
YoY Change 88.06% -59.58% 135.57%
Cash From Investing Activities $4.840M -$6.280M $4.520M
YoY Change 89.06% -58.95% 144.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 680.0K -120.0K 11.55M
YoY Change -250.0% -76.61%
NET CHANGE
Cash From Operating Activities -5.880M -7.370M -5.940M
Cash From Investing Activities 4.840M -6.280M 4.520M
Cash From Financing Activities 680.0K -120.0K 11.55M
Net Change In Cash -360.0K -13.77M 10.13M
YoY Change -79.89% -34.71% -78.27%
FREE CASH FLOW
Cash From Operating Activities -$5.880M -$7.370M -$5.940M
Capital Expenditures -$190.0K -$110.0K -$50.00K
Free Cash Flow -$5.690M -$7.260M -$5.890M
YoY Change 34.52% 23.68% 29.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
37482000
CY2017Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
3078000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12817000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-22207000
CY2016Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1215000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
71000
CY2017Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5220000
CY2016Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3726000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5629000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3965000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
111000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
132000
CY2017Q4 us-gaap Liabilities
Liabilities
5740000
CY2016Q4 us-gaap Liabilities
Liabilities
4097000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18143000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11453000
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9791728
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11296000
CY2017Q4 agle Working Capital
WorkingCapital
49400000
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-11473000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16670188
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13430833
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16670188
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13430833
CY2017 us-gaap Revenue From Grants
RevenueFromGrants
5205000
CY2016 us-gaap Revenue From Grants
RevenueFromGrants
4628000
CY2015 us-gaap Revenue From Grants
RevenueFromGrants
6085000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5947000
CY2017 us-gaap Investment Income Net
InvestmentIncomeNet
482000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-42000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
208000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
20000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-27236000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-21698000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-11295000
CY2015 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
228000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27236000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21698000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11523000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.80
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15128192
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-98000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27334000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21701000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
20000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
747000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
23000
CY2016 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
58311000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47266000
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
76000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1221000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
131000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11380000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2492000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
249000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
132000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
89000
CY2017 agle Payment For Discount Premium On Investments Net
PaymentForDiscountPremiumOnInvestmentsNet
-9000
CY2016 agle Payment For Discount Premium On Investments Net
PaymentForDiscountPremiumOnInvestmentsNet
146000
CY2015 agle Payment For Discount Premium On Investments Net
PaymentForDiscountPremiumOnInvestmentsNet
5000
CY2017 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
75000
CY2016 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
101000
CY2015 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
2000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
2492000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
1221000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
767000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-482000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1697000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
114000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
924000
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
15000
CY2016 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
110000
CY2015 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
812000
CY2017 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
21000
CY2016 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
10000
CY2015 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
19000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1863000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
586000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
164000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-169000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-51000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
71000
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1666000
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1829000
CY2015 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1119000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-24615000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18840000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10982000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
619000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
212000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
208000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
64115000
CY2016 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
20390000
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3766000
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
42205000
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
8446000
CY2016 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-80000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
40000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-22529000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-12076000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4014000
CY2015 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
43679000
CY2017 agle Proceeds From Issuance Of Common Stock Net Of Payments Of Offering Costs
ProceedsFromIssuanceOfCommonStockNetOfPaymentsOfOfferingCosts
11380000
CY2016 agle Proceeds From Issuance Of Common Stock Net Of Payments Of Offering Costs
ProceedsFromIssuanceOfCommonStockNetOfPaymentsOfOfferingCosts
49294000
CY2015 agle Proceeds From Issuance Of Common Stock Net Of Payments Of Offering Costs
ProceedsFromIssuanceOfCommonStockNetOfPaymentsOfOfferingCosts
-2028000
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
833000
CY2016 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
76000
CY2015 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
23000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12213000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
49370000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
41674000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-34931000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
18454000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
26678000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29294000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2616000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
57000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
172000
CY2015 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
232000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
296000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2673000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such management estimates include those related to accruals of research and development related costs, fair values of preferred and common shares and preferred and common stock, share/stock-based compensation, and certain company income tax related items. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to becoming a public company, the Company utilized significant estimates and assumptions in determining the fair value of its common shares and common stock. The board of directors determined the estimated fair value of common shares and common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, the price at which the Company sold shares of convertible preferred shares, the superior rights and preferences of securities senior to the Company&#8217;s common shares and common stock, and the marketability at the time. The Company utilized valuation methodologies in accordance with the American Institute of Certified Public Accountants Practice Guide, <font style="font-style:italic;">Audit and Accounting Practice Aid Series: Valuation of Privately-Held-Company Securities Issued as Compensation</font>, to estimate the fair value of common shares and common stock (see Notes 6, 9, and 11).</p></div>
CY2017 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Reclassification</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Certain reclassifications have been made to prior period amounts to conform to current period presentation. These reclassifications did not have an impact on the Company&#8217;s results of operations or financial position as of December&#160;31, 2017 and 2016.</p></div>
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5543000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-5483000
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
50300000
CY2017 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2016 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2015 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2015Q1 agle Number Of Subsidiary Corporations Owned
NumberOfSubsidiaryCorporationsOwned
7
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
8924000
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
8924000
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
37584000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
102000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
37482000
CY2016Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
43834000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
15758000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
15754000
CY2017Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
34498000
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
15754000
CY2017Q4 agle Available For Sale Securities Debt Maturities Year One Through Two Fair Value
AvailableForSaleSecuritiesDebtMaturitiesYearOneThroughTwoFairValue
2984000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1341000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
839000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
487000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
240000
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1837000
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1270000
CY2017Q4 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
2552000
CY2016Q4 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
1749000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
672000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
480000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
159000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
227000
CY2015Q1 us-gaap Partners Capital Account Distributions
PartnersCapitalAccountDistributions
0
CY2017 us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
a ratio of one share of common stock for each share of convertible preferred stock
CY2017 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.095
CY2016Q2 agle Shares Authorized
SharesAuthorized
510000000
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 agle Number Of Common Stock Voting Rights Held Per Share
NumberOfCommonStockVotingRightsHeldPerShare
1
CY2017 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each holder of common stock is entitled to one vote for each share of common stock held.
CY2017 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2017Q4 agle Number Of Classes Of Common Shares
NumberOfClassesOfCommonShares
3
CY2017 agle Common Stock Conversion Ratio
CommonStockConversionRatio
1
CY2017 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
each outstanding Common A-1 and Common A share was automatically converted into one share of common stock, par value $0.0001 per share
CY2015Q1 agle Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
253232
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
100446
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Number Of Employees Affected
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected
7
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1146935
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1971300
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
200600
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
556275
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2361360
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2351832
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
565920
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.64
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.22
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.50
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.76
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.21
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.22
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.47
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M20D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M19D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M19D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M18D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
440000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2482000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2464000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
318000
CY2016 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2015 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2014 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2016 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
333000
CY2015 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
307000
CY2017 agle Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
7869000
CY2017 agle Share Based Compensation Arrangement By Share Based Payment Award Nonvested Awards Lowest Potential Aggregate Fair Values
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedAwardsLowestPotentialAggregateFairValues
0
CY2016 agle Share Based Compensation Arrangement By Share Based Payment Award Nonvested Awards Lowest Potential Aggregate Fair Values
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedAwardsLowestPotentialAggregateFairValues
0
CY2015 agle Share Based Compensation Arrangement By Share Based Payment Award Nonvested Awards Lowest Potential Aggregate Fair Values
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedAwardsLowestPotentialAggregateFairValues
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
135000
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
51000
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2017Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
46406000
CY2016Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
59588000
CY2017Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017 us-gaap Fair Value Inputs Discount Rate
FairValueInputsDiscountRate
0.30
CY2017 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.70
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-9260000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7377000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3841000
CY2015 agle Income Tax Reconciliation Deductions Conversion Of Limited Liability Company From Partnership
IncomeTaxReconciliationDeductionsConversionOfLimitedLiabilityCompanyFromPartnership
21000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9369000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3876000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12170000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12286000
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
29000
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
38000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
333000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
335000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
386000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
283000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
75000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
76000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19389000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
16713000
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
63000
CY2016Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
60000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
63000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
60000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19326000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16653000
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
58000000
CY2016Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
36100000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q4 us-gaap Security Deposit Liability
SecurityDepositLiability
47000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
355000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
367000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
300000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1022000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
350000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
151000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
140000
CY2017Q1 us-gaap Revenue From Grants
RevenueFromGrants
982000
CY2017Q2 us-gaap Revenue From Grants
RevenueFromGrants
1479000
CY2017Q3 us-gaap Revenue From Grants
RevenueFromGrants
1261000
CY2017Q4 us-gaap Revenue From Grants
RevenueFromGrants
1483000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-6627000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-6483000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6301000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-4547000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-5430000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-6238000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.10
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2016Q1 us-gaap Revenue From Grants
RevenueFromGrants
859000
CY2016Q2 us-gaap Revenue From Grants
RevenueFromGrants
1373000
CY2016Q3 us-gaap Revenue From Grants
RevenueFromGrants
1149000
CY2016Q4 us-gaap Revenue From Grants
RevenueFromGrants
1247000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4567000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5495000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41

Files In Submission

Name View Source Status
0001564590-18-005404-index-headers.html Edgar Link pending
0001564590-18-005404-index.html Edgar Link pending
0001564590-18-005404.txt Edgar Link pending
0001564590-18-005404-xbrl.zip Edgar Link pending
agle-10k_20171231.htm Edgar Link pending
agle-20171231.xml Edgar Link completed
agle-20171231.xsd Edgar Link pending
agle-20171231_cal.xml Edgar Link unprocessable
agle-20171231_def.xml Edgar Link unprocessable
agle-20171231_lab.xml Edgar Link unprocessable
agle-20171231_pre.xml Edgar Link unprocessable
agle-ex1012_1673.htm Edgar Link pending
agle-ex1017_1102.htm Edgar Link pending
agle-ex231_10.htm Edgar Link pending
agle-ex311_9.htm Edgar Link pending
agle-ex312_8.htm Edgar Link pending
agle-ex321_6.htm Edgar Link pending
agle-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201803130216543793472.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending